{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:38:28Z","timestamp":1792600708373,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005758","name":"Universit\u00e0 Politecnica delle Marche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005758","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The rapid emergence of new synthetic opioids (NSOs), especially potent 2-benzylbenzimidazole derivatives known as nitazenes, poses challenges to public health and toxicologists. Among these substances, 5-methyl etodesnitazene has recently appeared on the illicit market. This compound was shown to be approximately twice as potent as fentanyl at the \u00b5-opioid receptor, and overdose may lead to potentially fatal respiratory depression. Detecting the drug and its metabolites is therefore critical for clinical and forensic investigations. This study aimed to characterize the metabolic profile of 5-methyl etodesnitazene in humans. Metabolic transformations were investigated through incubations with ten-donor pooled human hepatocytes and analysis of blood and urine samples from a postmortem case positive for 5-methyl etodesnitazene. Samples were analyzed using liquid chromatography-electrospray ionization-high-resolution tandem mass spectrometry (LC-ESI-HRMS\/MS) in positive- and negative-ionization modes, and software-aided data mining. In positive mode, 5-methyl etodesnitazene produced an intense signal in its di-protonated form, which generated informative spectra, facilitating structural elucidation. Biotransformations included\n                    <jats:italic>N<\/jats:italic>\n                    - and\n                    <jats:italic>O<\/jats:italic>\n                    -deethylation, consistent with structural analogs, as well as \u03c9-carboxylation specific to the methylated benzimidazole core; phase II metabolites were not detected. We suggest\n                    <jats:italic>N<\/jats:italic>\n                    -deethyl-5-methyl etodesnitazene,\n                    <jats:italic>N<\/jats:italic>\n                    -deethyl-5-carboxy etodesnitazene, and 5-carboxy etodesnitazene in blood, and\n                    <jats:italic>N<\/jats:italic>\n                    -deethyl-5-carboxy-4\u2032-hydroxy etodesnitazene, 5-carboxy-4\u2032-hydroxy etodesnitazene, and\n                    <jats:italic>N<\/jats:italic>\n                    -deethyl-5-carboxy etodesnitazene in urine, as metabolite biomarkers of consumption in clinical and forensic settings. Overall, metabolite profiles were consistent across in vitro and in vivo data, with minor matrix-specific differences. Considering that nitazene metabolites are often active and their metabolism is susceptible to genetic polymorphism, further research on the pharmacokinetics and pharmacodynamics of 5-methyl etodesnitazene is warranted.\n                  <\/jats:p>","DOI":"10.1007\/s00216-026-06472-8","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:11:43Z","timestamp":1777392703000},"page":"3679-3694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["5-Methyl etodesnitazene human metabolism: LC-ESI\u00b1-HRMS\/MS analysis (mono- and di-protonation) of human hepatocyte incubations and positive biospecimens"],"prefix":"10.1007","volume":"418","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0633-2117","authenticated-orcid":false,"given":"Omayema","family":"Taoussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-9518","authenticated-orcid":false,"given":"Jeremy","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3194-3250","authenticated-orcid":false,"given":"Prince S.","family":"Gameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4190-5469","authenticated-orcid":false,"given":"Laura M.","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8890-8677","authenticated-orcid":false,"given":"Giulia","family":"Bambagiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6452-5880","authenticated-orcid":false,"given":"Francesco","family":"Tavoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7814-8038","authenticated-orcid":false,"given":"Anastasio","family":"Tini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3005-5825","authenticated-orcid":false,"given":"Diletta","family":"Berardinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-4532","authenticated-orcid":false,"given":"Francesco P.","family":"Busard\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1883-2804","authenticated-orcid":false,"given":"Volker","family":"Auw\u00e4rter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"6472_CR1","unstructured":"United Nations Office on Drugs and Crime (UNODC). UNODC Early Warning Advisory on NPS - Summary Dashboard. 2024. https:\/\/www.unodc.org\/LSS\/Page\/NPS\/DataVisualisations. Accessed 15 Sep 2025."},{"key":"6472_CR2","unstructured":"United Nations Office on Drugs and Crime (UNODC). The challenge of New Psychoactive Substances-A technical update 2024. 2024. https:\/\/www.unodc.org\/documents\/scientific\/The_Challenge_of_NPS_A_technical_update_2024.pdf. Accessed 15 Sep 2025."},{"issue":"8","key":"6472_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/ADD.16420","volume":"119","author":"PN Griffiths","year":"2024","unstructured":"Griffiths PN, Seyler T, De Morais JM, Mounteney JE, Sedefov RS. Opioid problems are changing in Europe with worrying signals that synthetic opioids may play a more significant role in the future. Addiction. 2024;119(8):1334\u20136. https:\/\/doi.org\/10.1111\/ADD.16420.","journal-title":"Addiction"},{"key":"6472_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2017.00785","volume":"8","author":"S Pichini","year":"2017","unstructured":"Pichini S, Pacifici R, Marinelli E, Busard\u00f2 FP. European drug users at risk from illicit fentanyls mix. Front Pharmacol. 2017;8:785. https:\/\/doi.org\/10.3389\/FPHAR.2017.00785.","journal-title":"Front Pharmacol"},{"issue":"9","key":"6472_CR5","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/S00204-024-03774-7","volume":"98","author":"LM De Vrieze","year":"2024","unstructured":"De Vrieze LM, Walton SE, Pottie E, Papsun D, Logan BK, Krotulski AJ, et al. In vitro structure-activity relationships and forensic case series of emerging 2-benzylbenzimidazole \u201cnitazene\u201d opioids. Arch Toxicol. 2024;98(9):2999\u20133018. https:\/\/doi.org\/10.1007\/S00204-024-03774-7.","journal-title":"Arch Toxicol"},{"issue":"4","key":"6472_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1021\/ACSCHEMNEURO.3C00750","volume":"15","author":"MHM Tsai","year":"2024","unstructured":"Tsai MHM, Chen L, Baumann MH, Canals M, Javitch JA, Lane JR, et al. In vitro functional profiling of fentanyl and nitazene analogs at the \u03bc-opioid receptor reveals high efficacy for Gi protein signaling. ACS Chem Neurosci. 2024;15(4):854\u201367. https:\/\/doi.org\/10.1021\/ACSCHEMNEURO.3C00750.","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"6472_CR7","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00204-022-03294-2","volume":"96","author":"MM Vandeputte","year":"2022","unstructured":"Vandeputte MM, Verougstraete N, Walther D, Glatfelter GC, Malfliet J, Baumann MH, et al. First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass. Arch Toxicol. 2022;96(6):1865\u201380. https:\/\/doi.org\/10.1007\/s00204-022-03294-2.","journal-title":"Arch Toxicol"},{"issue":"8","key":"6472_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/15563650.2024.2383692","volume":"62","author":"R Syrjanen","year":"2024","unstructured":"Syrjanen R, Schumann JL, Castle JW, Sharp L, Griffiths A, Blakey K, et al. Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in Australia. Clin Toxicol. 2024;62(8):539\u201341. https:\/\/doi.org\/10.1080\/15563650.2024.2383692.","journal-title":"Clin Toxicol"},{"key":"6472_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCA.2024.119764","volume":"561","author":"A Ameline","year":"2024","unstructured":"Ameline A, Gheddar L, Pichini S, Stove C, Aknouche F, Maruejouls C, et al. In vitro characterization of protonitazene metabolites, using human liver microsomes, and first application to two urines collected from death cases. Clin Chim Acta. 2024;561:119764. https:\/\/doi.org\/10.1016\/J.CCA.2024.119764.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"6472_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/JAT\/BKAC062","volume":"47","author":"JL Schumann","year":"2023","unstructured":"Schumann JL, Syrjanen R, Alford K, Mashetty S, Castle JW, Rotella J, et al. Intoxications in an Australian Emergency Department involving \u201cnitazene\u201d benzylbenzimidazole synthetic opioids (etodesnitazene, butonitazene and protonitazene). J Anal Toxicol. 2023;47(1):e6. https:\/\/doi.org\/10.1093\/JAT\/BKAC062.","journal-title":"J Anal Toxicol"},{"issue":"1","key":"6472_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/S00414-024-03309-W","volume":"139","author":"C Maruejouls","year":"2025","unstructured":"Maruejouls C, Ameline A, Gheddar L, Mazoyer C, Teston K, Aknouche F, et al. First evidence in an oversea French department of the deadly risk of protonitazene use: about 5 post mortem cases. Int J Legal Med. 2025;139(1):87\u201393. https:\/\/doi.org\/10.1007\/S00414-024-03309-W.","journal-title":"Int J Legal Med"},{"issue":"4","key":"6472_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/FTD.0000000000000970","volume":"44","author":"E Montanari","year":"2022","unstructured":"Montanari E, Madeo G, Pichini S, Busard\u00f2 FP, Carlier J. Acute intoxications and fatalities associated with benzimidazole opioid (nitazene analog) use: a systematic review. Ther Drug Monit. 2022;44(4):494\u2013510. https:\/\/doi.org\/10.1097\/FTD.0000000000000970.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"6472_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/JAT\/BKAC083","volume":"47","author":"JL Schumann","year":"2023","unstructured":"Schumann JL, Syrjanen R, Alford K, Mashetty S, Castle JW, Rotella J, et al. Correction to: Intoxications in an Australian Emergency Department involving \u201cnitazene\u201d benzylbenzimidazole synthetic opioids (etodesnitazene, butonitazene and protonitazene). J Anal Toxicol. 2023;47(1):e21. https:\/\/doi.org\/10.1093\/JAT\/BKAC083.","journal-title":"J Anal Toxicol"},{"key":"6472_CR14","unstructured":"European Union Drugs Agency (EUDA). European drug report 2023: Trends and developments. 2024. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2023_en. Accessed 15 Sep 2025."},{"key":"6472_CR15","doi-asserted-by":"publisher","unstructured":"Bangura RA, Mayei A, Fatoma P, Bunting-Graden JA, Kaisam JP, Ansumana R. Beyond the smoke: A phenomenological study of health and social implications of Kush use among Sierra Leonean youths. 2024. https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2024.04.24.24306083v1. Accessed 15 Sep 2025.","DOI":"10.1101\/2024.04.24.24306083v1"},{"key":"6472_CR16","unstructured":"European Union Drugs Agency (EUDA). New psychoactive substances-the current situation in Europe (European Drug Report 2024). https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025\/new-psychoactive-substances_en. Accessed 15 Sep 2025."},{"key":"6472_CR17","unstructured":"European Union Drugs Agency (EUDA). EU drug market: Heroin and other opioids \u2014 Retail markets. 2024. https:\/\/www.euda.europa.eu\/publications\/eu-drug-markets\/heroin-and-other-opioids\/retail-markets_en. Accessed 15 Sep 2025."},{"key":"6472_CR18","unstructured":"European Union Drugs Agency (EUDA). European drug report 2025: Trends and developments. 2025. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2025_en. Accessed 15 Sep 2025."},{"key":"6472_CR19","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EU Early Warning System intensive monitoring. 2023. https:\/\/workpage.ews-nfp.bg\/wp-content\/uploads\/2023\/12\/EU-EWS-IM-2023-0003-Etomethazene-under-intensive-monitoring.pdf. Accessed 15 Sep 2025."},{"key":"6472_CR20","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EU Early Warning System formal notification. 2023. https:\/\/workpage.ews-nfp.bg\/wp-content\/uploads\/2023\/11\/EU-EWS-RCS-FN-2023-0004_etomethazene-1.pdf. Accessed 15 Sep 2025."},{"key":"6472_CR21","unstructured":"Walton SE, Roberts D, Altomare-Jarczyk C, Edelmann A, Davis J, Denn MT, Quinter AD, DeBord JS, Green T, Logan BK, Krotulski AJ. 5-Methyl etodesnitazene - NPS Discovery new drug monograph, Center for Forensic Science Research and Education (CFSRE). 2024. https:\/\/www.cfsre.org\/nps-discovery\/monographs\/5-methyl-etodesnitazene. Accessed 15 Sep 2025."},{"key":"6472_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2024.107503","volume":"210","author":"MM Vandeputte","year":"2024","unstructured":"Vandeputte MM, Glatfelter GC, Walther D, Layle NK, St. Germaine DM, Ujv\u00e1ry I, et al. Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro \u00b5-opioid receptor assays and in vivo behavioral studies in mice. Pharmacol Res. 2024;210:107503. https:\/\/doi.org\/10.1016\/J.PHRS.2024.107503.","journal-title":"Pharmacol Res"},{"issue":"2","key":"6472_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/JPET.123.002052","volume":"389","author":"LB Kozell","year":"2024","unstructured":"Kozell LB, Eshleman AJ, Wolfrum KM, Swanson TL, Bloom SH, Benware S, et al. Pharmacologic characterization of substituted nitazenes at \u03bc, \u03ba, and \u0394 opioid receptors suggests high potential for toxicity. J Pharmacol Exp Ther. 2024;389(2):219\u201328. https:\/\/doi.org\/10.1124\/JPET.123.002052.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6472_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/S00213-022-06292-5","volume":"240","author":"SE Walton","year":"2023","unstructured":"Walton SE, Krotulski AJ, Glatfelter GC, Walther D, Logan BK, Baumann MH. Plasma pharmacokinetics and pharmacodynamic effects of the 2-benzylbenzimidazole synthetic opioid, isotonitazene, in male rats. Psychopharmacology (Berl). 2023;240(1):185\u201398. https:\/\/doi.org\/10.1007\/S00213-022-06292-5.","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"6472_CR25","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/S00204-024-03735-0","volume":"98","author":"O Taoussi","year":"2024","unstructured":"Taoussi O, Berardinelli D, Zaami S, Tavoletta F, Basile G, Kronstrand R, et al. Human metabolism of four synthetic benzimidazole opioids: Isotonitazene, metonitazene, etodesnitazene, and metodesnitazene. Arch Toxicol. 2024;98(7):2101\u201316. https:\/\/doi.org\/10.1007\/S00204-024-03735-0.","journal-title":"Arch Toxicol"},{"issue":"8","key":"6472_CR26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1515\/CCLM-2023-1360","volume":"62","author":"D Berardinelli","year":"2024","unstructured":"Berardinelli D, Taoussi O, Carlier J, Tini A, Zaami S, Sundermann T, et al. In vitro, in vivo metabolism and quantification of the novel synthetic opioid N-piperidinyl etonitazene (etonitazepipne). Clin Chem Lab Med. 2024;62(8):1580\u201390. https:\/\/doi.org\/10.1515\/CCLM-2023-1360.","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"6472_CR27","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/BIOINFORMATICS\/BTZ695","volume":"36","author":"C Stork","year":"2020","unstructured":"Stork C, Embruch G, \u0160\u00edcho M, De Bruyn Kops C, Chen Y, Svozil D, et al. NERDD: a web portal providing access to in in silico tools for drug discovery. Bioinformatics. 2020;36(4):1291\u20132. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTZ695.","journal-title":"Bioinformatics"},{"issue":"2","key":"6472_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1021\/ACS.CHEMRESTOX.0C00224","volume":"34","author":"C De Bruyn Kops","year":"2021","unstructured":"De Bruyn Kops C, \u0160\u00edcho M, Mazzolari A, Kirchmair J. GLORYx: prediction of the metabolites resulting from phase 1 and phase 2 biotransformations of xenobiotics. Chem Res Toxicol. 2021;34(2):286\u201399. https:\/\/doi.org\/10.1021\/ACS.CHEMRESTOX.0C00224.","journal-title":"Chem Res Toxicol"},{"key":"6472_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCHROMB.2022.123162","volume":"1193","author":"J Carlier","year":"2022","unstructured":"Carlier J, Berardinelli D, Montanari E, Sirignano A, Di Trana A, Busard\u00f2 FP. 3F-\u03b1-pyrrolydinovalerophenone (3F-\u03b1-PVP) in vitro human metabolism: multiple in silico predictions to assist in LC-HRMS\/MS analysis and targeted\/untargeted data mining. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1193:123162. https:\/\/doi.org\/10.1016\/J.JCHROMB.2022.123162.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"6472_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPBA.2023.115759","author":"O Taoussi","year":"2024","unstructured":"Taoussi O, Gameli PS, Berardinelli D, Busard\u00f2 FP, Tini A, Carlier J. In silico and in vitro human metabolism of IOX2, a performance-enhancing doping agent. J Pharm Biomed Anal. 2024. https:\/\/doi.org\/10.1016\/J.JPBA.2023.115759.","journal-title":"J Pharm Biomed Anal"},{"key":"6472_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.TALANTA.2021.122740","volume":"235","author":"A Di Trana","year":"2021","unstructured":"Di Trana A, Brunetti P, Giorgetti R, Marinelli E, Zaami S, Busard\u00f2 FP, et al. In in silico prediction, LC-HRMS\/MS analysis, and targeted\/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolites. Talanta. 2021;235:122740. https:\/\/doi.org\/10.1016\/J.TALANTA.2021.122740.","journal-title":"Talanta"},{"issue":"7","key":"6472_CR32","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/S00204-022-03289-Z","volume":"96","author":"FP Busard\u00f2","year":"2022","unstructured":"Busard\u00f2 FP, Lo Faro AF, Sirignano A, Giorgetti R, Carlier J. In in silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common \u201cdiuretic and masking agent\u201d in doping. Arch Toxicol. 2022;96(7):1989\u20132001. https:\/\/doi.org\/10.1007\/S00204-022-03289-Z.","journal-title":"Arch Toxicol"},{"key":"6472_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-025-04163-4","author":"D Berardinelli","year":"2025","unstructured":"Berardinelli D, Taoussi O, Ovat Y, Pichini S, Auw\u00e4rter V, Pulver B, et al. Busard\u00f2 FP (2024) Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on \u00b5-opioid receptor docking simulations. Arch Toxicol. 2025. https:\/\/doi.org\/10.1007\/s00204-025-04163-4.","journal-title":"Arch Toxicol"},{"key":"6472_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116453","volume":"251","author":"MC Monti","year":"2024","unstructured":"Monti MC, De Vrieze LM, Vandeputte MM, Persson M, Gr\u00e9en H, Stove CP, et al. Detection of N-desethyl etonitazene in a drug checking sample: chemical analysis and pharmacological characterization of a recent member of the 2-benzylbenzimidazole \u201cnitazene\u201d class. J Pharm Biomed Anal. 2024;251:116453. https:\/\/doi.org\/10.1016\/j.jpba.2024.116453.","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"6472_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/jat\/bkad071","volume":"47","author":"M Sch\u00fcller","year":"2023","unstructured":"Sch\u00fcller M, Lucic I, \u00d8iestad \u00c5ML, Pedersen-Bjergaard S, \u00d8iestad EL. High-throughput quantification of emerging \u201cnitazene\u201d benzimidazole opioid analogs by microextraction and UHPLC-MS-MS. J Anal Toxicol. 2023;47(9):787\u201396. https:\/\/doi.org\/10.1093\/jat\/bkad071.","journal-title":"J Anal Toxicol"},{"issue":"3","key":"6472_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/JAT\/BKAB117","volume":"46","author":"SE Walton","year":"2022","unstructured":"Walton SE, Krotulski AJ, Logan BK. A forward-thinking approach to addressing the new synthetic opioid 2-benzylbenzimidazole nitazene analogs by liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS). J Anal Toxicol. 2022;46(3):221\u201331. https:\/\/doi.org\/10.1093\/JAT\/BKAB117.","journal-title":"J Anal Toxicol"},{"issue":"7","key":"6472_CR37","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1021\/JASMS.4C00200","volume":"35","author":"AL Hollerbach","year":"2024","unstructured":"Hollerbach AL, Lin VS, Ibrahim YM, Ewing RG, Metz TO, Rodda KE. Elucidating the gas-phase behavior of nitazene analog protomers using structures for lossless ion manipulations ion mobility-orbitrap mass spectrometry. J Am Soc Mass Spectrom. 2024;35(7):1609\u201321. https:\/\/doi.org\/10.1021\/JASMS.4C00200.","journal-title":"J Am Soc Mass Spectrom"},{"key":"6472_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2024.1434573","volume":"15","author":"GR Jadhav","year":"2024","unstructured":"Jadhav GR, Fasinu PS. Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes. Front Pharmacol. 2024;15:1434573. https:\/\/doi.org\/10.3389\/FPHAR.2024.1434573.","journal-title":"Front Pharmacol"},{"issue":"6","key":"6472_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/JAT\/BKAA016","volume":"44","author":"AJ Krotulski","year":"2020","unstructured":"Krotulski AJ, Papsun DM, Kacinko SL, Logan BK. Isotonitazene quantitation and metabolite discovery in authentic forensic casework. J Anal Toxicol. 2020;44(6):521\u201330. https:\/\/doi.org\/10.1093\/JAT\/BKAA016.","journal-title":"J Anal Toxicol"},{"issue":"10","key":"6472_CR40","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/DTA.3115","volume":"13","author":"AJ Krotulski","year":"2021","unstructured":"Krotulski AJ, Papsun DM, Walton SE, Logan BK. Metonitazene in the United States\u2014forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry. Drug Test Anal. 2021;13(10):1697\u2013711. https:\/\/doi.org\/10.1002\/DTA.3115.","journal-title":"Drug Test Anal"},{"key":"6472_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109939","volume":"249","author":"MM Vandeputte","year":"2023","unstructured":"Vandeputte MM, Tsai MHM, Chen L, Glatfelter GC, Walther D, Stove CP, et al. Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. Drug Alcohol Depend. 2023;249:109939. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109939.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"6472_CR42","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","volume":"12","author":"MM Vandeputte","year":"2021","unstructured":"Vandeputte MM, Van Uytfanghe K, Layle NK, St. Germaine DM, Iula DM, Stove CP. Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci. 2021;12(7):1241\u201351. https:\/\/doi.org\/10.1021\/acschemneuro.1c00064.","journal-title":"ACS Chem Neurosci"},{"key":"6472_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.chroma.2016.11.059","volume":"1478","author":"SN Atapattu","year":"2016","unstructured":"Atapattu SN, Poole CF, Praseuth MB. System maps for retention of small neutral compounds on a biphenylsiloxane-bonded silica stationary phase in reversed-phase liquid chromatography. J Chromatogr A. 2016;1478:68\u201374. https:\/\/doi.org\/10.1016\/j.chroma.2016.11.059.","journal-title":"J Chromatogr A"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-026-06472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00216-026-06472-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-026-06472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:57:53Z","timestamp":1780041473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00216-026-06472-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["6472"],"URL":"https:\/\/doi.org\/10.1007\/s00216-026-06472-8","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human biological samples were submitted to the Institute of Forensic Medicine, Forensic Toxicology, Medical Center \u2013 University of Freiburg for routine toxicological analysis. No personal or identifying data such as gender, age, body weight, amount and timing of intake, co-ingestion of other substances, or storage conditions were available. In\u00a0vitro experiments were conducted using pooled human hepatocytes obtained from commercial sources. No animal experiments were performed in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The study was performed exclusively on anonymized biological postmortem samples originally collected for routine clinical or forensic toxicological purposes. As the analyses were performed within routine casework and no additional sampling or identifiable data were involved, no ethical approval or additional informed consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}